SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System

Core Insights - SINTX Technologies has successfully completed clinical evaluations of its product, OsseoSculpt™, leading to early commercial momentum and the first recorded revenue in Q3 2025 [1][3] Product Overview - OsseoSculpt™ features a nanocrystalline HCA surface with a biomimetic pore architecture, enhancing osteoconductive properties and providing a scaffold for bone healing [2] - The product is designed to complement the SINAPTIC® Foot & Ankle Osteotomy Wedge System, which is engineered for stable correction in foot and ankle procedures [4] Commercial Strategy - The company has executed a private label agreement to market OsseoSculpt™ alongside the SINAPTIC wedge system, aiming to streamline the surgical process for healthcare providers [1][3] - Initial orders indicate real-world demand, with a limited release through select design and early-adopter sites [7] Market Positioning - The combination of SINAPTIC wedges and OsseoSculpt™ addresses a critical gap in surgical care, as noted by the positive feedback from design surgeons [3][7] - The broader rollout in the U.S. is planned to align with the availability of the wedge system and surgeon training cycles, targeting Q4 2025 to Q1 2026 [7] Growth Drivers - Key growth drivers include targeted in-service education, case support, and data capture on attach rates, procedure times, and outcomes to support evidence-driven adoption [7]